Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.38 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649822 | 0.95 | C5AR1 (0.39) | TLR7CACNA2D1C5AR1BCHEMAPT | |
| SCHEMBL648391 | 0.94 | C5AR1 (0.38) | TLR7C5AR1BCHEMAPTALDH1A1 | |
| SCHEMBL650072 | 0.94 | C5AR1 (0.41) | TLR7C5AR1BCHEMAPTALDH1A1 | |
| SCHEMBL653383 | 0.93 | C5AR1 (0.39) | TLR7CACNA2D1C5AR1BCHEMAPT | |
| SCHEMBL650215 | 0.93 | C5AR1 (0.38) | TLR7C5AR1BCHEMAPTALDH1A1 | |
| SCHEMBL649888 | 0.93 | C5AR1 (0.40) | CACNA2D1C5AR1BCHEMAPTALDH1A1 | |
| SCHEMBL651651 | 0.92 | C5AR1 (0.39) | TLR7CACNA2D1C5AR1MAPTALDH1A1 | |
| SCHEMBL650750 | 0.92 | MAPT (0.36) | C5AR1BCHEMAPTALDH1A1HTT | |
| SCHEMBL1913033 | 0.92 | TLR7 (0.39) | TLR7CACNA2D1C5AR1BCHEMAPT | |
| SCHEMBL650506 | 0.92 | C5AR1 (0.37) | TLR7C5AR1BCHEMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |